BioSpace News Archive

Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021.

Sapience Therapeutics, Inc., announced today that it has commenced dosing in the final dose-escalation cohort of an ongoing Phase 1-2 study of its lead program, ST101, for the treatment of patients with advanced and metastatic solid tumors.

Two new publications in respected medical journals further examine the importance of high-flux dialyzers in maintaining serum albumin levels in hemodialysis patients, Fresenius Medical Care North America (FMCNA) announced today.

Microbion Corporation of Bozeman, MT, announced that Mr. Robert A. Gillam, CFA, will be joining Microbion’s Board of Directors as Chairman, replacing Mr. Karim Lalji in the Board Chairman role effective immediately.

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, announced today it has completed enrollment in its first-in-human study evaluating the company’s Amplifi™ Vein Dilation System.

Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront.

Mycovia Pharmaceuticals, Inc. (Mycovia), today announced that data from its Phase 3, randomized, double-blind, placebo-controlled VIOLET studies to measure the efficacy and safety of oteseconazole (VT-1161) for the treatment of recurrent vulvovaginal candidiasis (RVVC) will be presented at the 2021 Virtual Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG).

Ocular Therapeutix, Inc. (NASDAQ:OCUL), today announced that it has dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (wet AMD).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights.